27351941|t|Treatment with high dose of atorvastatin reduces vascular injury in diabetic rats
27351941|a|Previous reports showed conflicting results regarding the treatment effects of statin on Diabetes mellitus (DM). We investigated how treatment with high dose of atorvastatin affects the impaired vascular function in diabetic rats. Atorvastatin (80mg/kg/day, oral gavage, 4 weeks) or its vehicle was administered to male control or streptozotocin (STZ)-induced diabetic rats. Aortic segments were used to investigate the vascular reactivity, protein expression of cyclooxygenase-2 (COX-2) and nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) 1 (NOX1) and superoxide anions levels. Atorvastatin treatment did not affect glycemia levels. In diabetic rats, the vascular reactivity to phenylephrine increased compared with controls and the atorvastatin treatment reduced this response. Removal of the endothelium increased the response to phenylephrine in control rats, but not in the diabetic group. Atorvastatin increased the endothelial modulation in diabetic rats. L-NAME (100μM) increased the reactivity in all groups, but this effect was greater in atorvastatin -treated diabetic rats. Indomethacin (10μM) and NS398 (1μM) decreased the contractile response in diabetic rats and atorvastatin reversed these effects, without changing COX-2 expression. Apocynin (30μM) decreased the phenylephrine response in diabetic rats, which also showed increased NOX1 and superoxide anions; these effects were prevented by atorvastatin treatment. The results suggest that treatment with high dose of atorvastatin, independent of glycemia, improves endothelial function in aortas from diabetic rats by reducing the constrictor prostanoids derived from COX-2 and by reducing the oxidative stress by NADPH oxidase, as well as a possible increasing of nitric oxide participation.
27351941	0	9	Treatment	T061	C0087111
27351941	15	24	high dose	T081	C0444956
27351941	28	40	atorvastatin	T109,T121	C0286651
27351941	49	64	vascular injury	T037	C0178324
27351941	68	76	diabetic	T047	C0011849
27351941	77	81	rats	T015	C0086893
27351941	140	149	treatment	T061	C0087111
27351941	161	167	statin	T109,T121	C0360714
27351941	171	188	Diabetes mellitus	T047	C0011849
27351941	190	192	DM	T047	C0011849
27351941	215	224	treatment	T061	C0087111
27351941	230	239	high dose	T081	C0444956
27351941	243	255	atorvastatin	T109,T121	C0286651
27351941	268	276	impaired	T169	C0221099
27351941	277	294	vascular function	T201	C0232337
27351941	298	306	diabetic	T047	C0011849
27351941	307	311	rats	T015	C0086893
27351941	313	325	Atorvastatin	T109,T121	C0286651
27351941	340	351	oral gavage	T169	C2698653
27351941	355	360	weeks	T079	C0439230
27351941	369	376	vehicle	T122	C0042444
27351941	381	393	administered	T169	C1521801
27351941	397	409	male control	T096	C0009932
27351941	413	427	streptozotocin	T109,T195	C0038432
27351941	429	432	STZ	T109,T195	C0038432
27351941	442	450	diabetic	T047	C0011849
27351941	451	455	rats	T015	C0086893
27351941	457	472	Aortic segments	T023	C0506947
27351941	502	521	vascular reactivity	T201	C1660757
27351941	523	541	protein expression	T045	C1171362
27351941	545	561	cyclooxygenase-2	T116,T126	C0387583
27351941	563	568	COX-2	T116,T126	C0387583
27351941	574	643	nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) 1	T116,T126	C1417769
27351941	645	649	NOX1	T116,T126	C1417769
27351941	655	672	superoxide anions	T196	C0038836
27351941	673	679	levels	T080	C0441889
27351941	681	693	Atorvastatin	T109,T121	C0286651
27351941	694	703	treatment	T061	C0087111
27351941	719	734	glycemia levels	T059	C0392201
27351941	739	747	diabetic	T047	C0011849
27351941	748	752	rats	T015	C0086893
27351941	758	777	vascular reactivity	T201	C1660757
27351941	781	794	phenylephrine	T109,T121	C0031469
27351941	795	804	increased	T081	C0205217
27351941	819	827	controls	T167	C1550141
27351941	836	848	atorvastatin	T109,T121	C0286651
27351941	849	858	treatment	T061	C0087111
27351941	859	866	reduced	T080	C0392756
27351941	872	880	response	T032	C0871261
27351941	882	889	Removal	T052	C1883720
27351941	897	908	endothelium	T024	C0014257
27351941	909	918	increased	T081	C0205217
27351941	923	931	response	T032	C0871261
27351941	935	948	phenylephrine	T109,T121	C0031469
27351941	952	964	control rats	T096	C0009932
27351941	981	995	diabetic group	UnknownType	C0681860
27351941	997	1009	Atorvastatin	T109,T121	C0286651
27351941	1010	1019	increased	T081	C0205217
27351941	1024	1046	endothelial modulation	UnknownType	C0544633
27351941	1050	1058	diabetic	T047	C0011849
27351941	1059	1063	rats	T015	C0086893
27351941	1065	1071	L-NAME	T116,T123	C0083536
27351941	1080	1089	increased	T081	C0205217
27351941	1094	1104	reactivity	T169	C0443286
27351941	1112	1118	groups	UnknownType	C0681860
27351941	1151	1163	atorvastatin	T109,T121	C0286651
27351941	1173	1181	diabetic	T047	C0011849
27351941	1182	1186	rats	T015	C0086893
27351941	1188	1200	Indomethacin	T109,T121	C0021246
27351941	1212	1217	NS398	T109,T121	C1567346
27351941	1224	1233	decreased	T081	C0205216
27351941	1238	1249	contractile	T026	C1511498
27351941	1250	1258	response	T032	C0871261
27351941	1262	1270	diabetic	T047	C0011849
27351941	1271	1275	rats	T015	C0086893
27351941	1280	1292	atorvastatin	T109,T121	C0286651
27351941	1293	1301	reversed	T169	C1555029
27351941	1308	1315	effects	T080	C1280500
27351941	1334	1339	COX-2	T116,T126	C0387583
27351941	1340	1350	expression	T045	C1171362
27351941	1352	1360	Apocynin	T109,T121	C0050465
27351941	1368	1377	decreased	T081	C0205216
27351941	1382	1395	phenylephrine	T109,T121	C0031469
27351941	1396	1404	response	T032	C0871261
27351941	1408	1416	diabetic	T047	C0011849
27351941	1417	1421	rats	T015	C0086893
27351941	1441	1450	increased	T081	C0205217
27351941	1451	1455	NOX1	T116,T126	C1417769
27351941	1460	1477	superoxide anions	T196	C0038836
27351941	1485	1492	effects	T080	C1280500
27351941	1511	1523	atorvastatin	T109,T121	C0286651
27351941	1524	1533	treatment	T061	C0087111
27351941	1539	1546	results	T169	C1274040
27351941	1560	1569	treatment	T061	C0087111
27351941	1575	1584	high dose	T081	C0444956
27351941	1588	1600	atorvastatin	T109,T121	C0286651
27351941	1602	1616	independent of	T169	C0332291
27351941	1617	1625	glycemia	T109	C0005802
27351941	1636	1647	endothelial	T024	C0014257
27351941	1648	1656	function	T169	C0542341
27351941	1660	1666	aortas	T023	C0003483
27351941	1672	1680	diabetic	T047	C0011849
27351941	1681	1685	rats	T015	C0086893
27351941	1689	1697	reducing	T080	C0392756
27351941	1702	1725	constrictor prostanoids	T109,T121,T125	C0033554
27351941	1739	1744	COX-2	T116,T126	C0387583
27351941	1752	1760	reducing	T080	C0392756
27351941	1765	1781	oxidative stress	T049	C0242606
27351941	1785	1798	NADPH oxidase	T116,T126	C0068355
27351941	1822	1832	increasing	T169	C0442808
27351941	1836	1848	nitric oxide	T121,T123,T197	C0028128
27351941	1849	1862	participation	T169	C0679823